focus -WSS

focus

author：fashion 2025-08-26 23:44:39 - browse：98747

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Weight loss drug costs may need more research, senator suggests

WSS

Does good food count as health care? Study aims to find out

It's time to get medical device identifiers over the finish line

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Hospitals look to new technology to keep health care workers safe

Living with Fabry disease, a condition that causes chronic pain

In key trial, Verve's treatment lowers cholesterol levels in patients

explore

focus

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Astellas still sees hope in its gene therapy after four deaths

In Memoriam: Notable people who died in 2023

Surge of respiratory disease in China has likely explanation

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Moonlake's readout produced a cash windfall. Risks remain

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Does good food count as health care? Study aims to find out

hotspot

Ransomware attacks on hospitals: Study outlines patient impact

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Elizabeth Holmes on track for early release from her 11

Retired US general questions alleged Putin, Prigozhin meeting

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

HCA discloses massive data breach affecting 11 million patients

entertainment

hotspot

focus

focus